Genitourinary Cancer—Kidney and Bladder

 
Chung-Han Lee, Martin H Voss, Maria Isabel Carlo,  et al.
The study authors conclude that Nivolumab plus cabozantinib showed an acceptable safety profile and promising efficacy in metastatic non-clear cell renal cell carcinoma with papillary, unclassified, or translocation-associated histologies. Activity in patients with chromophobe renal cell carcinoma was limited. Clinical trial information: NCT03635892
 
 
Michael B. Atkins, Opeyemi Jegede, Naomi B. Haas, et al.
The study authors conclude that nivolumab monotherapy showed limited activity in naïve nccRCC. Most responses (4 of 5) were seen in patients with sarcomatoid and/or unclassified tumors. No new Toxicity was observed with nivolumab. Salvage treatment with nivolumab/ipilimumab received 16 of 28 (57%) patients with progressive disease/or stable disease at 48 wks on nivolumab monotherapy, with 1 response observed. Clinical trial information: NCT03117309
 
 
Cristina Suarez Rodriguez, James Larkin, Poulam M. Patel, et al.
The study authors conclude that the combination of savolitinib and durvalumab has clinical activity in MET-driven PRC. Clinical trial information: NCT02819596
 
 
Xinan Sheng, Dingwei Ye, Ai-Ping Zhou, et al.
The study authors conclude that vorolanib plus everolimus showed a progression-free survival benefit for metastatic RCC which has progressed after one previous VEGF-targeted therapy with a safe tolerance profile. Clinical trial information: NCT03095040
 
 
Luis A Meza, Nazli Dizman, Paulo Gustavo Bergerot, et al.
The study authors conclude that this prospective study suggests enhancement of immune checkpoint inhibitor response with a live bacterial product. The observed clinical impact is corroborated by biological findings supporting gut modulation by CBM-588. Butyrate-producing bacterium Clostridium butyricum is the key constituent of CBM-588. Clinical trial information: NCT03829111
 
  
Laurence Albiges, Martin H Voss, Brian I. Rini,  et al.
The study authors conclude that In patients with aRCC who received 2L CT following 1L treatment with A + Ax, long-term overall and progression-free survival (PFS2) were observed. Clinical trial information: NCT02684006
 
Hamid Emamekhoo, Mark R Olsen, Bradley Curtis Carthon,  et al.
The study authors conclude that In previously untreated aRCC and brain metastases the approved treatment regimen of nivolumab plus ipilimumab followed by nivolumab for aRCC showed no new safety signals. This treatment continues to show encouraging antitumor activity with longer follow-up. Clinical trial information: NCT02982954
 
 
Jaleh Fallah, Haley Gittleman, Chana Weinstock,  et al.
The study authors conclude that nephrectomy prior to Immunotherapy-based combination therapies in patients with new diagnosises of stage IV RCC appeared to be associated with improved overall survival. This was even observed, when controlling for age and prognostic risk group. The authors state that decision for nephrectomy is affected by factors such as medical comorbidities which could not be completely controlled. The authors characterize their results as hypothesis-generating.
 
 
Samuel Aaron Funt, Michael Lattanzi, Karissa Whiting,  et al.
The study authors conclude that Neoadjuvant gemcitabine and cisplatin + atezolizumab is effective and safe for muscle-invasive bladder cancer. The PD-L1 positivity rate was low compared with other studies and not predictive of pathologic downstaging. Clinical trial information: NCT02989584
 
 
Petros Grivas, Jun Yin, Vadim S Koshkin, et al.
The study authors conclude that neoadjuvant nivolumab alone and the combination of nivolumab plus lirilumab prior to RC were safe, feasible, and well-tolerated in cisplatin-ineligible patients with muscle-invasive bladder cancer. However, ypT0N0 rates were unexpectedly low, especially with nivolumab alone. Clinical trial information: NCT03532451
 
 
Thomas Powles, Daniel P. Petrylak, Se Hoon Park, et al.
The study authors conclude that an overall survival benefit was seen for avelumab 1st-line maintenance plus best supportive care versus best supportive care alone across subgroups of interest. These results are consistent with previously reported findings reported in the NEJM. This is further supporting avelumab 1st-line maintenance as a standard of care for patients with advanced urothelial carcinoma that has not progressed with 1st-line platinum-containing chemotherapy. Clinical trial information: NCT02603432
 
POSTER SESSION:
 
Srikala S. Sridhar, Thomas Powles, Yohann Loriot, et al.
The study authors conclude that In advanced urothelial carcinoma that had not progressed with 1st-line platinum-containing chemotherapy, avelumab 1st-line maintenance prolonged overall survival irrespective of the treatment-free interval assessed in this study (4-10weeks).   This supports this new treatment strategy as a standard of care. Differences in the duration of treatment-free interval were likely related to the individual patient- and disease-specific characteristics or logistic. It did not impact the overall survival benefit observed with avelumab 1st-line maintenance. Clinical trial information: NCT02603432